Cargando…

Correction to Organometallic Iridium(III) Anticancer Complexes with New Mechanisms of Action: NCI-60 Screening, Mitochondrial Targeting, and Apoptosis

Detalles Bibliográficos
Autores principales:	Hearn, Jessica M., Romero-Canelon, Isolda, Qamar, Bushra, Liu, Zhe, Hands-Portman, Ian, Sadler, Peter J.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	American Chemical Society 2013
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3805325/ http://dx.doi.org/10.1021/cb400715w

Ejemplares similares

Organometallic Iridium(III) Anticancer Complexes with New Mechanisms of Action: NCI-60 Screening, Mitochondrial Targeting, and Apoptosis
por: Hearn, Jessica M., et al.
Publicado: (2013)

Enhancement of Selectivity of an Organometallic Anticancer Agent by Redox Modulation
por: Romero-Canelón, Isolda, et al.
Publicado: (2015)

Potent Half-Sandwich Iridium(III) Anticancer Complexes Containing C(∧)N-Chelated and Pyridine Ligands
por: Liu, Zhe, et al.
Publicado: (2014)

Contrasting Anticancer Activity of Half-Sandwich Iridium(III) Complexes Bearing Functionally Diverse 2-Phenylpyridine Ligands
por: Millett, Adam J., et al.
Publicado: (2015)

Strategies for conjugating iridium(III) anticancer complexes to targeting peptides via copper-free click chemistry
por: Zhang, Wen-Ying, et al.
Publicado: (2019)

The Potent Oxidant Anticancer Activity of Organoiridium Catalysts**
por: Liu, Zhe, et al.
Publicado: (2014)

New activation mechanism for half-sandwich organometallic anticancer complexes
por: Banerjee, Samya, et al.
Publicado: (2018)

Mitochondria-targeted spin-labelled luminescent iridium anticancer complexes
por: Venkatesh, V., et al.
Publicado: (2017)

Synchrotron X‐Ray Fluorescence Nanoprobe Reveals Target Sites for Organo‐Osmium Complex in Human Ovarian Cancer Cells
por: Sanchez‐Cano, Carlos, et al.
Publicado: (2017)

Transfer hydrogenation catalysis in cells as a new approach to anticancer drug design
por: Soldevila-Barreda, Joan J., et al.
Publicado: (2015)

Novel iridium (III)-derived organometallic compound for the inhibition of human platelet activation
por: Shyu, Kou-Gi, et al.
Publicado: (2018)

Novel iridium (III)-derived organometallic compound for the inhibition of human platelet activation
por: Shyu, Kou-Gi, et al.
Publicado: (2019)

New Therapeutic Agent against Arterial Thrombosis: An Iridium(III)-Derived Organometallic Compound
por: Hsia, Chih-Wei, et al.
Publicado: (2017)

Ir-6: A Novel Iridium (III) Organometallic Derivative for Inhibition of Human Platelet Activation
por: Shyu, Ren-Shi, et al.
Publicado: (2018)

Mirror-Image Organometallic Osmium Arene Iminopyridine Halido Complexes Exhibit Similar Potent Anticancer Activity
por: Fu, Ying, et al.
Publicado: (2013)

NMR studies of group 8 metallodrugs: (187)Os-enriched organo-osmium half-sandwich anticancer complex
por: Needham, Russell J., et al.
Publicado: (2021)

Integrating Constitutive Gene Expression and Chemoactivity: Mining the NCI60 Anticancer Screen
por: Covell, David G.
Publicado: (2012)

Organometallic Anticancer Compounds
por: Gasser, Gilles, et al.
Publicado: (2010)

Photoactivatable Cell-Selective Dinuclear trans-Diazidoplatinum(IV) Anticancer Prodrugs
por: Shi, Huayun, et al.
Publicado: (2018)

Cell Death Mechanism of Organometallic Ruthenium(II) and Iridium(III) Arene Complexes on HepG2 and Vero Cells
por: Kavukcu, Serdar Batıkan, et al.
Publicado: (2023)

In‐Cell Activation of Organo‐Osmium(II) Anticancer Complexes
por: Needham, Russell J., et al.
Publicado: (2016)

Lysosomal Targeted Cyclometallic Iridium(Ⅲ) Salicylaldehyde-Coumarin Schiff Base Complexes and Anticancer Application
por: Xu, Ruixi, et al.
Publicado: (2022)

On the Best Way to Cluster NCI-60 Molecules
por: Hernández-Hernández, Saiveth, et al.
Publicado: (2023)

Theranostic Lysosomal Targeting Anticancer and Antimetastatic Agents: Half-Sandwich Iridium(III) Rhodamine Complexes
por: Ma, Wenli, et al.
Publicado: (2019)

In Vivo Selectivity and Localization of Reactive Oxygen Species (ROS) Induction by Osmium Anticancer Complexes That Circumvent Platinum Resistance
por: Coverdale, James P. C., et al.
Publicado: (2018)

Ester-Modified Cyclometalated Iridium(III) Complexes as Mitochondria-Targeting Anticancer Agents
por: Wang, Fang-Xin, et al.
Publicado: (2016)

Ruthenium(II) and Iridium(III) Complexes as Tested Materials for New Anticancer Agents
por: Masternak, Joanna, et al.
Publicado: (2020)

Integrated metabolome and transcriptome analysis of the NCI60 dataset
por: Su, Gang, et al.
Publicado: (2011)

Prediction of anticancer molecules using hybrid model developed on molecules screened against NCI-60 cancer cell lines
por: Singh, Harinder, et al.
Publicado: (2016)

Enhancing the Activity of Drugs by Conjugation to Organometallic Fragments
por: Chellan, Prinessa, et al.
Publicado: (2020)

Recombination phenotypes of the NCI-60 collection of human cancer cells
por: Stults, Dawn M, et al.
Publicado: (2011)

An integrated analysis of molecular aberrations in NCI-60 cell lines
por: Yeang, Chen-Hsiang
Publicado: (2010)

Expression of MicroRNAs in the NCI-60 Cancer Cell-Lines
por: Patnaik, Santosh K., et al.
Publicado: (2012)

Quantitative Proteome Landscape of the NCI-60 Cancer Cell Lines
por: Guo, Tiannan, et al.
Publicado: (2019)

Targeting cancer lactate metabolism with synergistic combinations of synthetic catalysts and monocarboxylate transporter inhibitors
por: Bridgewater, Hannah E., et al.
Publicado: (2023)

Oncosis-inducing cyclometalated iridium(iii) complexes
por: Guan, Ruilin, et al.
Publicado: (2018)

Imidazole and Benzimidazole Modified Half-Sandwich Iridium(III) N-Heterocyclic Carbene Complexes: Synthesis, Anticancer Application, and Organelle Targeting
por: Liu, Xicheng, et al.
Publicado: (2020)

Cyclometalated iridium(iii) complexes as lysosome-targeted photodynamic anticancer and real-time tracking agents
por: He, Liang, et al.
Publicado: (2015)

Anticancer evaluation of new organometallic ruthenium(ii) flavone complexes
por: Khater, Mai, et al.
Publicado: (2022)

HLA class I and II genotype of the NCI-60 cell lines
por: Adams, Sharon, et al.
Publicado: (2005)

Cannot write session to /tmp/vufind_sessions/sess_2mdll800je6lbpb0cgjpues0ma